FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 359:2495-2497 December 4, 2008 Number 23 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Lovell, D. J. PubMed Citation

To the Editor: Lovell et al. (Aug. 21 issue)¹ report that adalimumab seems to be effective in the treatment of children with juvenile rheumatoid arthritis. However, interpretation of their results is difficult, given the medication-withdrawal design of the trial. During the open-label lead-in phase, patients who had a response to the drug were preselected and children who could not tolerate it were excluded. The double-blind phase was therefore enriched with patients who had a response to the drug, and the treatment effects observed may be larger than those seen in an unselected population.

The evaluation of safety also raises some . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.